CVRx Q4 2024 revenue $15.3M (+36% YoY); FY2025 revenue guidance $63-65M

CVRx, Inc.

2024-FY EPS reported -$2.65 revenue$51,292,000

Q4 2024 total revenue $15.3M, +36% YoY; U.S. HF revenue $14.3M, +41% YoY (457 units vs 330).
FY2024 total revenue $51.3M, +31% YoY; net loss $60.0M ($2.65 per share) vs $41.2M in FY2023.
Active implanting centers grew to 223 as of Dec 31, 2024, up 25% from 178 a year earlier.
FY2025 guidance: total revenue $63-65M, gross margin 83-84%, operating expenses $100-104M.
Cash and cash equivalents $105.9M as of Dec 31, 2024; net cash used in ops/investing $40.5M in FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.